Anti-Human EGFR Reference Antibody (MM-151, RUO) (HF004376)

Name: Anti-Human EGFR Reference Antibody (MM-151, RUO)
Brand: abinScience
SKU: HF004376
Price: 370 USD
Availability: InStock

Datasheet Compartir producto Copiar información

Precio(USD):

Especificación:

100ug
1mg
5mg
10mg
25mg
50mg
100mg

Número:

Contáctenos

Vista general
Imágenes
Referencias
Datasheet
SDS

Vista general

Número de catálogo	HF004376
Reactividad de especies	Human
Aplicaciones	ELISA, Bioactivity: FCM, Functional assay, Research in vivo
Especie huésped	Human
Clonalidad	Monoclonal
Isotipo	IgG
ID de clon	MM-151
Objetivo	EC:2.7.10.1, EGFR, ERBB, ERBB1, Epidermal growth factor receptor, HER1, Proto-oncogene c-ErbB-1, Receptor tyrosine-protein kinase erbB-1
Nivel de endotoxinas	< 10 EU/mg
Pureza	>95% as determined by SDS-PAGE.
Purificación	Protein A/G purified from cell culture supernatant.
Número de acceso	P00533
Forma	Liquid
Buffer de almacenamiento	0.01M PBS pH 7.4. Consulte la información específica del buffer en la copia impresa del datasheet o en el COA específico del lote.
Estabilidad y almacenamiento	Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Nombres alternativos	MM-151, MM151, MM151
Fondo	Epidermal growth factor receptor (EGFR/ERBB1) is a ~134 kDa protein. Receptor tyrosine kinase binding ligands of the EGF family and activating several signaling cascades to convert extracellular cues into appropriate cellular responses. Known ligands include EGF, TGFA/TGF-alpha, AREG, epigen/EPGN, BTC/betacellulin, epiregulin/EREG and HBEGF/heparin-binding EGF. Ligand binding triggers receptor homo- and/or heterodimerization and autophosphorylation on key cytoplasmic residues. The phosphorylated receptor recruits adapter proteins like GRB2 which in turn activates complex downstream signaling cascades. Activates at least 4 major downstream signaling cascades including the RAS-RAF-MEK-ERK, PI3 kinase-AKT, PLCgamma-PKC and STATs modules. EGFR is the therapeutic target of cetuximab (Erbitux) and panitumumab (Vectibix). 1. Arcaro, A. et al. (2000) Molecular and cellular biology 20, 3817-30. PMID: 10805725 2. Runkle, KB. et al. (2016) Molecular cell 62, 385-396. PMID: 27153536 3. Chen, WS. et al. (1989) Cell 59, 33-43. PMID: 2790960 4. Bu, J. et al. (2022) Acta biochimica et biophysica Sinica 54, 400-408. PMID: 35538033 5. Garrett, TP. et al. (2002) Cell 110, 763-73. PMID: 12297049 6. Kochupurakkal, BS. et al. (2005) The Journal of biological chemistry 280, 8503-12. PMID: 15611079 7. Kim, J. et al. (2007) Cancer research 67, 9229-37. PMID: 17909029 8. Lu, C. et al. (2010) Molecular and cellular biology 30, 5432-43. PMID: 20837704
Referencias	1. Arena S, et al. MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations. Sci Transl Med. 2016 Feb 3;8(324):324ra14. [HF004376] 2. Kearns JD, et al. Enhanced Targeting of the EGFR Network with MM-151, an Oligoclonal Anti-EGFR Antibody Therapeutic. Mol Cancer Ther. 2015 Jul;14(7):1625-36. [HF004376]
Nota	For research use only. Not suitable for clinical or therapeutic use.